Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Immunotherapy for Combatting Genitourinary Tract Cancers
share announcement

Immunotherapy for Combatting Genitourinary Tract Cancers

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 8923

Special Issue Editor

Dr. Hyewon Lee

E-Mail
Guest Editor
Department of Urology, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si 10408, Gyeonggi-do, Korea
Interests: genitourinary tract cancer; immunotherapy; tumor microenvironment; tumor evolution; resistance to immunotherapy; combinational therapeutic strategies using chemotherapy, targeted therapy, radiotherapy and immunotherapy; novel immune-modulatory agents, including adaptive T cell therapy, CAR-T cells and vaccines; predictive biomarkers to immunotherapy; radiomics for monitoring and assessing real clinical response to immunotherapy

Special Issue Information

Dear Colleagues，

Nowadays, the immunotherapeutic approach, such as using immune checkpoint inhibitors, has been widely applied as an alternative effective option against advanced genitourinary tract cancers that are refractory to first-line chemotherapies and targeted agents. Despite enhanced clinical efficacy and reduced side effects, more reliable predictive biomarkers, combination strategies to overcome limited efficacy and therapeutic resistance of single immunotherapy, novel innovative immune-modulatory tools should be investigated through comprehensive translational research for optimized personalized immunotherapy. In this Special Issue, high-quality original research articles, review papers, and meta-analysis papers will be invited and considered for peer-reviewed publication.

Dr. Hyewon Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • advanced urothelial carcinoma (transitional cell carcinoma) in the upper urinary tract and bladder
  • advanced renal cell carcinoma
  • castration-resistant prostate cancer
  • tumor-immune microenvironment
  • combinational approaches for boosting the therapeutic effects of immunomodulatory agents
  • novel predictive biomarkers for immunotherapy
  • tumor-intrinsic or extrinsic mechanisms contributing to the resistance to immunotherapy
  • preclinical or translational

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 3811 KiB  
Article
Intravesical High Dose BCG Tokyo and Low Dose BCG Tokyo with GMCSF+IFN α Induce Systemic Immunity in a Murine Orthotopic Bladder Cancer Model
by Sin Mun Tham, Juwita N. Rahmat, Edmund Chiong, Qinghui Wu, Kesavan Esuvaranathan and Ratha Mahendran
Biomedicines 2021, 9(12), 1766; https://doi.org/10.3390/biomedicines9121766 - 25 Nov 2021
Cited by 2 | Viewed by 2402
Abstract
This study evaluates a short therapy schedule for bladder cancer using BCG Tokyo. BCG Tokyo was evaluated in vitro using bone marrow derived dendritic cells, neutrophils, RAW macrophages and the murine bladder cancer cell line, MB49PSA, and compared to other BCG strains. BCG [...] Read more.
This study evaluates a short therapy schedule for bladder cancer using BCG Tokyo. BCG Tokyo was evaluated in vitro using bone marrow derived dendritic cells, neutrophils, RAW macrophages and the murine bladder cancer cell line, MB49PSA, and compared to other BCG strains. BCG Tokyo > BCG TICE at inducing cytokine production. In vivo, high dose (1 × 107 colony forming units (cfu)) and low dose (1 × 106 cfu) BCG Tokyo with and without cytokine genes (GMCSF + IFNα) were evaluated in C57BL/6J mice (n = 12–16 per group) with orthotopically implanted MB49PSA cells. Mice were treated with four instillations of cytokine gene therapy and BCG therapy. Both high dose BCG alone and low dose BCG combined with cytokine gene therapy were similarly effective. In the second part the responsive groups, mice (n = 27) were monitored by urinary PSA analysis for a further 7 weeks after therapy cessation. More mice were cured at day 84 than at day 42 confirming activation of the immune system. Cured mice resisted the re-challenge with subcutaneous tumors unlike naïve, age matched mice. Antigen specific T cells recognizing BCG, HY and PSA were identified. Thus, fewer intravesical instillations, with high dose BCG Tokyo or low dose BCG Tokyo with GMCSF + IFNα gene therapy, can induce effective systemic immunity. Full article
(This article belongs to the Special Issue Immunotherapy for Combatting Genitourinary Tract Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 1014 KiB  
Review
Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day
by Brigida Anna Maiorano, Ugo De Giorgi, Davide Ciardiello, Giovanni Schinzari, Antonio Cisternino, Giampaolo Tortora and Evaristo Maiello
Biomedicines 2022, 10(2), 411; https://doi.org/10.3390/biomedicines10020411 - 9 Feb 2022
Cited by 15 | Viewed by 2975
Abstract
Background: In advanced bladder cancer (BCa), platinum-based chemotherapy represents the first-choice treatment. In the last ten years, immune checkpoint inhibitors (ICIs) have changed the therapeutic landscape of many solid tumors. Our review aims to summarize the main findings regarding the clinical use of [...] Read more.
Background: In advanced bladder cancer (BCa), platinum-based chemotherapy represents the first-choice treatment. In the last ten years, immune checkpoint inhibitors (ICIs) have changed the therapeutic landscape of many solid tumors. Our review aims to summarize the main findings regarding the clinical use of ICIs in advanced BCa. Methods: We searched PubMed, Embase, and Cochrane databases, and conference abstracts from international congresses (ASCO, ESMO, ASCO GU) for clinical trials, focusing on ICIs as monotherapy and combinations in metastatic BCa. Results: 18 studies were identified. ICIs targeting PD1 (nivolumab, pembrolizumab), PD-L1 (avelumab, atezolizumab, durvalumab), and CTLA4 (ipilimumab, tremelimumab) were used. Survival outcomes have been improved by second-line ICIs, whereas first-line results are dismal. Avelumab maintenance in patients obtaining disease control with chemotherapy has achieved the highest survival rates. Conclusions: ICIs improve survival after platinum-based chemotherapy. Avelumab maintenance represents a new practice-changing treatment. The combinations of ICIs and other compounds, such as FGFR-inhibitors, antibody-drug conjugates, and anti-angiogenic drugs, represent promising therapeutic approaches. Biomarkers with predictive roles and sequencing strategies are warranted for best patient selection. Full article
(This article belongs to the Special Issue Immunotherapy for Combatting Genitourinary Tract Cancers)
►▼ Show Figures

Figure 1

14 pages, 1582 KiB  
Review
Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology
by Hae Woong Choi, Manisha Naskar, Ho Kyung Seo and Hye Won Lee
Biomedicines 2021, 9(11), 1500; https://doi.org/10.3390/biomedicines9111500 - 20 Oct 2021
Cited by 4 | Viewed by 2874
Abstract
Urothelial bladder cancer (UBC) is one of the most prevalent and aggressive malignancies. Recent evidence indicates that the tumor microenvironment (TME), including a variety of immune cells, is a critical modulator of tumor initiation, progression, evolution, and treatment resistance. Mast cells (MCs) in [...] Read more.
Urothelial bladder cancer (UBC) is one of the most prevalent and aggressive malignancies. Recent evidence indicates that the tumor microenvironment (TME), including a variety of immune cells, is a critical modulator of tumor initiation, progression, evolution, and treatment resistance. Mast cells (MCs) in UBC are possibly involved in tumor angiogenesis, tissue remodeling, and immunomodulation. Moreover, tumor-infiltration by MCs has been reported in early-stage UBC patients. This infiltration is linked with a favorable or unfavorable prognosis depending on the tumor type and location. Despite the discrepancy of MC function in tumor progression, MCs can modify the TME to regulate the immunity and infiltration of tumors by producing an array of mediators. Nonetheless, the precise role of MCs in UBC tumor progression and evolution remains unknown. Thus, this review discusses some critical roles of MCs in UBC. Patients with UBC are treated at both early and late stages by immunotherapeutic methods, including intravenous bacillus Calmette–Guérin instillation and immune checkpoint blockade. An understanding of the patient response and resistance mechanisms in UBC is required to unlock the complete potential of immunotherapy. Since MCs are pivotal to understand the underlying processes and predictors of therapeutic responses in UBC, our review also focuses on possible immunotherapeutic treatments that involve MCs. Full article
(This article belongs to the Special Issue Immunotherapy for Combatting Genitourinary Tract Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop